| Rx0000297 |
MannKind Corporation |
09/30/2022 |
47918089190 |
Afrezza 12 Unit Inhalation Powder Metered 1 Carton |
07/01/2022 |
83.50 |
1276.36 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2022 |
47918087490 |
Afrezza 4 Unit Inhalation Powder Metered 1 Carton |
07/01/2022 |
27.83 |
425.44 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2022 |
47918088018 |
Afrezza 4 Unit; 8 Unit Inhalation Powder Metered 1 Carton |
07/01/2022 |
83.50 |
1276.36 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2022 |
47918090218 |
Afrezza 4 Unit; 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton |
07/01/2022 |
111.33 |
1701.82 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2022 |
47918087890 |
Afrezza 8 Unit Inhalation Powder Metered 1 Carton |
07/01/2022 |
55.67 |
850.91 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
09/30/2022 |
47918089818 |
Afrezza 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton |
07/01/2022 |
139.17 |
2127.27 |
07/12/2032 |
Single Source Drug |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
09/30/2022 |
51862051260 |
Calcipotriene 0.005% 60g Foam |
09/15/2022 |
153.02 |
918.12 |
05/07/2028 |
Non-innovator Multiple Source Drug |
2270 |
None |
Annual WAC Increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
09/30/2022 |
51862029550 |
Fabior 0.1% 50g Foam |
09/15/2022 |
123.68 |
742.10 |
02/24/2030 |
Innovator Multiple Source Drug |
47995 |
None |
Annual WAC Increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
12/31/2022 |
50261011008 |
Imvexxy Maintenance Pack Vaginal Insert 10 MCG 8pack |
10/01/2022 |
9.29 |
215.64 |
02/02/2034 |
Single Source Drug |
None |
1 |
annual price increase |
None |
None |
None |
12/30/2022 |
THERAPEUTICS MD |
153100000 |
None |
For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments. |
215.64 |
196.52 |
2018 |
180.00 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
12/31/2022 |
50261010408 |
Imvexxy Maintenance Pack Vaginal Insert 4 MCG 8pack |
10/01/2022 |
9.29 |
215.64 |
02/02/2034 |
Single Source Drug |
None |
1 |
annual price increase |
None |
None |
None |
12/30/2022 |
THERAPEUTICS MD |
153100000 |
None |
For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments. |
215.64 |
196.52 |
2018 |
180.00 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
12/31/2022 |
50261011018 |
Imvexxy Starter Pack Vaginal Insert 10 MCG 18pack |
10/01/2022 |
20.89 |
485.18 |
02/02/2034 |
Single Source Drug |
None |
1 |
annual price increase |
None |
None |
None |
12/30/2022 |
THERAPEUTICS MD |
153100000 |
None |
For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments. |
485.18 |
442.18 |
2018 |
405.00 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
12/31/2022 |
50261010418 |
Imvexxy Starter Pack Vaginal Insert 4 MCG 18pack |
10/01/2022 |
20.89 |
485.18 |
02/02/2034 |
Single Source Drug |
None |
1 |
annual price increase |
None |
None |
None |
12/30/2022 |
THERAPEUTICS MD |
153100000 |
None |
For entire bucket of TXMD products, approximately $153.1 million (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments. |
485.18 |
442.18 |
2018 |
405.00 |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
09/30/2022 |
51862037660 |
Sorilux 0.005% 60g Foam |
09/15/2022 |
177.30 |
1063.82 |
05/07/2028 |
Innovator Multiple Source Drug |
9171 |
None |
Annual WAC Increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
09/30/2022 |
68308068550 |
Tazarotene 0.1% 50g Foam |
09/15/2022 |
106.74 |
640.46 |
02/24/2030 |
Non-innovator Multiple Source Drug |
10975 |
None |
Annual WAC Increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000382 |
Melinta Therapeutics, LLC |
03/31/2022 |
70842016010 |
MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (1mg dose) |
02/15/2022 |
205.00 |
2276.00 |
05/12/2031 |
Single Source Drug |
None |
1 |
Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors.
Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary. |
None |
None - see cost increase factors statement. |
None |
01/05/2018 |
The Medicines Company |
None |
1 |
None |
1544.13 |
1544.13 |
2015 |
1470.60 |
None |
None |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2022 |
00006412102 |
GARDASIL 9 0.5 mL Syringes 10 |
08/12/2022 |
151.71 |
2680.23 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
• investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2022 |
00006411903 |
GARDASIL 9 0.5 mL Vials 10 |
08/12/2022 |
151.71 |
2680.23 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
• investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2022 |
00006417100 |
PROQUAD 0.5 mL Vials 10 |
08/12/2022 |
123.51 |
2593.67 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
• investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000138 |
Merck Sharp & Dohme LLC |
09/30/2022 |
00006482700 |
VARIVAX 0.5 mL Vials 10 |
08/12/2022 |
90.14 |
1592.41 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity.
• investments in research and development that last year alone totaled nearly $12.2 billion ($115 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) The WAC price does not include the Federal Excise Tax (FET). |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2022 |
72495020105 |
FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE |
01/01/2022 |
54.66 |
636.11 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
485.37 |
443.67 |
2003 |
76.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2022 |
72495020210 |
FEMRING 0.10mFEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGEG |
01/01/2022 |
58.25 |
677.86 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
517.23 |
472.79 |
2003 |
81.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2022 |
72495040128 |
INTRAROSA 6.5mg/DAY (PRASTERONE INSERTS) |
01/01/2022 |
14.02 |
240.12 |
03/19/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/26/2020 |
AMAG |
None |
1 |
None |
212.30 |
202.00 |
2017 |
175.00 |
None |
None |
| Rx0000046 |
Mylan Specialty LP |
09/30/2022 |
49502080693 |
Yupelri (revefenacin) inhalation solution 175mcg/3mL, 30 vials |
07/05/2022 |
56.80 |
1216.01 |
08/25/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |